Better diagnose hematological disorders for confident decision making

The Myeloid Solution™ (MYS) by SOPHiA GENETICS is a CE-IVD marked molecular diagnostic application that bundles a capture-based target enrichment kit with the analytical power of SOPHiA™ AI and full access to SOPHiA DDM® platform.

The solution was expertly designed to accurately characterize the complex mutational landscape of the major hematological disorders associated with MDS1, MPN2 and leukemia. Characterization of driver mutations is critical for the understanding of the disease etiology and helps to stratify molecular cancer subtypes, thus improving clinical outcomes.

Benefits of the solution

Comprehensive

Detection of all types of genomic alterations (i.e SNVs, Indels and CNVs) in all the genes of the panel associated with hematological disorders

Accurate

Proven clinical-grade analytical performance 

Robust

Excellent coverage uniformity in all the genes of the panel, unlocking unmatched detection of complex variants in genes such as CEBPA, FLT3, ASXL1 and CALR

Flexible

Compatible with market-leading sequencing platforms without impact on performance. The gene panel can also be adapted according to experts' needs

 

1: MDS: myelodysplastic syndromes

2: MPN: myeloproliferative neoplasms